SHIKARI® (S-ATCER) Anti-Certolizumab ELISA w/confirmation

This kit has been especially developed for the quantitative antibodies to Certolizumab in serum and plasma samples.
All SHIKARI® ELISA kits are suitable for biosimilar work. All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

Please contact us at for specific academic pricing.

Background

Certolizumab Drug Bank Accession Number is DB08904.
Certolizumab pegol is a tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis. Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life.

More Details